Clinical activity and safety of cediranib and olaparib combination in patients with metastatic pancreatic ductal adenocarcinoma without BRCA mutation

CONCLUSION: Cediranib and olaparib combination did not result in clinically meaningful activity in patients with mPDAC without gBRCAmt.PMID:33742489 | DOI:10.1002/onco.13758

Source: The Oncologist - March 20, 2021 Category: Cancer & Oncology Authors: Joseph Kim Dana Cardin Ulka Vaishampayan Shumei Kato Steven Grossman Peter Glazer Yu Shyr S Ivy Patricia LoRusso Source Type: research